Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer by Seungyeul Yoo, Ayushi S. Patel, Sarah Karam, Yi Zhong, Li Wang, Feng Jiang, Ranran Kong, Sharon Bikvan, Wenhui Wang, Abhilasha Sinha, Charles A. Powell, Jun Zhu, Hideo Watanabe

“…In concordance with these findings, GRN-low tumors showed significantly better survival with chemo-immunotherapy, while GRN-high tumors did not benefit from additional immunotherapy. …”
Get full text

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy by Coraline Radermecker, Pascale Hubert, Patrick Roncarati, Stephanie Demoulin, Charlotte Pilard, Marie Ancion, Celia Reynders, Thomas Lerho, Diane Bruyere, Alizee Lebeau, Margot Meunier, Marie-Julie Nokin, Elodie Hendrick, Olivier Peulen, Philippe Delvenne, Michael Herfs

“…Journal for ImmunoTherapy of Cancer…”
Get full text

Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer by Hirotaka Matsumoto, Hiroaki Akamatsu, Nobuyuki Yamamoto, Yuki Sato, Daichi Fujimoto, Yoshihiko Taniguchi, Motohiro Tamiya, Yasuhiro Koh, Junya Fukuoka, Hisashi Tanaka, Naoki Furuya, Ryota Shibaki, Tsukasa Nozawa, Akira Sano, Yuka Kitamura, Takashi Kijima, Toshihide Yokoyama, Satoru Miura, Akito Hata, Jun Sugisaka

“…Journal for ImmunoTherapy of Cancer…”
Get full text

Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target by Guang-zhao Huang, Ze-qun Chen, Juan Wu, Ting-ru Shao, Chen Zou, Yi-long Ai, Xiao-zhi Lv

Get full text

Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model by Zimin Zhang, Mingyang Zhu, Weiwei Jiang

Subjects: Get full text

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy by Xin Liu, Yang Du, Ningyan Zhang, Zhiqiang An, Wei Xiong, Yixiang Xu, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Tianhao Duan, Helen Y Wang, John S. Yu, Rongfu Wang

“…Journal for ImmunoTherapy of Cancer…”
Get full text

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma by Laura M. Moser, Laura M. Moser, Laura M. Moser, Laura M. Moser, Laura M. Moser, Catrin Heim, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Philipp Wendel, Philipp Wendel, Philipp Wendel, Philipp Wendel, Süleyman Bozkurt, Sabine Harenkamp, Hermann Kreyenberg, Hermann Kreyenberg, Michael Merker, Michael Merker, Christian Münch, Christian Münch, Christian Münch, Elise Gradhand, Meike Vogler, Meike Vogler, Meike Vogler, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Halvard Bönig, Halvard Bönig, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Peter Bader, Peter Bader, Peter Bader, Peter Bader, Peter Bader, Winfried S. Wels, Winfried S. Wels, Winfried S. Wels, Eva Rettinger, Eva Rettinger, Eva Rettinger, Eva Rettinger, Eva Rettinger

Get full text

Neoadjuvant immunotherapy for DNA mismatch repair proficient/microsatellite stable non-metastatic rectal cancer: a systematic review and meta-analysis by Huan Zhang, Jing Huang, Huanji Xu, Nanhao Yin, Nanhao Yin, Liyan Zhou, Liyan Zhou, Jianxin Xue, Jianxin Xue, Jianxin Xue, Min Ren

Subjects: “…neoadjuvant immunotherapy…”
Get full text

Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy by Fermín E. González, Alexey Chernobrovkin, Cristián Pereda, Tamara García-Salum, Andrés Tittarelli, Mercedes N. López, Flavio Salazar-Onfray, Roman A. Zubarev

“…Autologous dendritic cells (DCs) loaded with cancer cell-derived lysates have become a promising tool in cancer immunotherapy. During the last decade, we demonstrated that vaccination of advanced melanoma patients with autologous tumor antigen presenting cells (TAPCells) loaded with an allogeneic heat shock- (HS-) conditioned melanoma cell-derived lysate (called TRIMEL) is able to induce an antitumor immune response associated with a prolonged patient survival. …”
Get full text

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer by Huiping Qiang, Yue Wang, Yao Zhang, Jingwen Li, Lincheng Zhang, Huawei Du, Xuxinyi Ling, Shuhui Cao, Yan Zhou, Runbo Zhong, Hua Zhong

“…First-line chemotherapy combined with immunotherapy has been the standard therapeutic regimen for KRAS-mutant NSCLC patients. …”
Get full text

FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers by Yongchang Tang, Hong Wang, Jiankun Zhang, Chunhui Yang, Fei Xu, Yan Song, Tianen Li, Qiangbo Zhang

Subjects: Get full text

Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma by Angela J. Yoon, Richard D. Carvajal, Evan M. Graboyes, John M. Kaczmar, William G. Albergotti, Alexandra E. Kejner, Scott H. Troob, Elizabeth Philipone, Jean-Sebastien Anoma, Kent E. Armeson, Elizabeth G. Hill, Mary S. Richardson, Tina R. Woods, Bhishamjit S. Chera, Farzad Nourollah-Zadeh, Byung J. Lee, Subramanya Pandruvada, Antonis Kourtidis, Christina Kingsley, Elizabeth C. O’Quinn, Stephanie Mills, Victoria C. Jordan, Mike Spencer, Danielle Fails, Trevor D. McKee, Mark Zaidi, Alan Brisendine, Shane Horn, Shikhar Mehrotra, Besim Ogretmen, Jason G. Newman

Subjects: Get full text

Combination of ataxia telangiectasia and Rad3-related inhibition with ablative radiotherapy remodels the tumor microenvironment and enhances immunotherapy response in lung cancer by Jenny Ling-Yu Chen, Chun-Kai Pan, Li-Cheng Lin, Yu-Sen Huang, Tsung-Hsuan Huang, Shu-Jyuan Yang, Sung-Hsin Kuo, Yu-Li Lin

“…Cancer Immunology, Immunotherapy…”
Get full text

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression by Jianfeng Peng, Xueying Zhai, Xiaomei Liu, Zhaoqin Huang, Yimeng Wang, Peizhu Wu, Ran Gao, Xiangjiao Meng

Subjects: Get full text

LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy by Zhishui Chen, Gang Chen, Li Chen, Xiangli Zhao, Lingjuan Sun, Zhibo Ma, Xiaosheng Tan, Yuhao Tu, Jingzeng Wang, Peixiang Lan

“…Journal for ImmunoTherapy of Cancer…”
Get full text

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients by Amalia Azzariti, Simona De Summa, Tommaso M. Marvulli, Ivana De Risi, Giuseppe De Palma, Roberta Di Fonte, Rossella Fasano, Simona Serratì, Sabino Strippoli, Letizia Porcelli, Michele Guida

Get full text

Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis by Zihao Chen, Xin Chen, Dingchao Li, Jingang jian, Chang Yao, Xuedong Wei, Jianquan Hou

Subjects: Get full text

Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer by Nicolas Captier, Marvin Lerousseau, Fanny Orlhac, Narinée Hovhannisyan-Baghdasarian, Marie Luporsi, Erwin Woff, Sarah Lagha, Paulette Salamoun Feghali, Christine Lonjou, Clément Beaulaton, Andrei Zinovyev, Hélène Salmon, Thomas Walter, Irène Buvat, Nicolas Girard, Emmanuel Barillot

“…Abstract Immunotherapy is improving the survival of patients with metastatic non-small cell lung cancer (NSCLC), yet reliable biomarkers are needed to identify responders prospectively and optimize patient care. …”
Get full text

Different In Situ Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy by Zheng-Hao Ye, Hao Long, Ze-Rui Zhao

“…Background. Neoadjuvant immunotherapy is promising for locally advanced non-small-cell lung cancer (NSCLC). …”
Get full text

Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4 by Zongyu Liu, Hongyu Chu, Weidong Zhao, Chenguang Yang, Tongjun Liu, Na Shen, Zhaohui Tang

Subjects: Get full text